Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00778167 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

NIH

Sponsor class

Conditions

Recurrent Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: cixutumumab
DRUG: erlotinib hydrochloride
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)